What works better than tirzepatide?

Few compounds have beaten tirzepatide in trials, which produced about 21% weight loss at 72 weeks at its top dose. Two Lilly programs have gone further. Retatrutide (GLP-3R) reached up to 28.3% at 80 weeks in its phase 3 TRIUMPH-1 trial, though not head to head with tirzepatide. In the SURMOUNT-5 trial, tirzepatide itself beat semaglutide, 20.2% versus 13.7% at 72 weeks.

The most direct comparison so far adds amylin. In a 48-week phase 2 trial in type 2 diabetes, eloralintide plus tirzepatide reached up to 23.3% weight loss, compared with 14.8% for tirzepatide 15 mg alone. Those are investigational results, and combination pivotal trials are still ahead. Our eloralintide vs GLP-3R comparison covers the data. Shop eloralintide for combination research.

ELORALINTIDE 10MG
ELORALINTIDE 10MG